

# Functional motor recovery from brain ischemic insult by carbon nanotube-mediated siRNA silencing

Khuloud T. Al-Jamal<sup>a,b,1</sup>, Lisa Gherardini<sup>c,1</sup>, Giuseppe Bardì<sup>c,1,2</sup>, Antonio Nunes<sup>a</sup>, Chang Guo<sup>a</sup>, Cyrill Bussy<sup>a</sup>, M. Antonia Herrero<sup>d</sup>, Alberto Bianco<sup>e</sup>, Maurizio Prato<sup>f</sup>, Kostas Kostarelos<sup>a,3</sup>, and Tommaso Pizzorusso<sup>c,g,3</sup>

<sup>a</sup>Nanomedicine Laboratory, Center for Drug Delivery Research, School of Pharmacy, University of London, London WC1N 1AX, United Kingdom; <sup>b</sup>Consiglio Nazionale delle Ricerche Neuroscience Institute, Pisa Area della ricerca Via G. Moruzzi 1, 56100 Pisa, Italy; <sup>c</sup>Departamento de Química Orgánica, Facultad de Química-IRICA, Universidad de Castilla-La Mancha, 13071 Ciudad Real, Spain; <sup>d</sup>CNRS, Institut de Biologie Moléculaire et Cellulaire, UPR 9021 Immunologie et Chimie Thérapeutiques, 67000 Strasbourg, France; <sup>e</sup>Department of Pharmaceutical Sciences, Center of Excellence for Nanostructured Materials, University of Trieste, Piazzale Europa 1, 34127 Trieste, Italy; <sup>f</sup>Department of Psychology, University of Florence, Area San Salvi, 50135 Firenze, Italy; and <sup>g</sup>Institute of Pharmaceutical Science, King's College London, Franklin-Wilkins Building, London SE1 9NH, United Kingdom

Edited\* by Sumio Iijima, Meijo University, Nagoya, Japan, and approved May 20, 2011 (received for review January 20, 2011)

Stroke is the second cause of death worldwide with ischemic stroke accounting for 80% of all stroke insults. Caspase-3 activation contributes to brain tissue loss and downstream biochemical events that lead to programmed cell death after traumatic brain injury. Alleviation of symptoms following ischemic neuronal injury can be potentially achieved by either genetic disruption or pharmacological inhibition of caspases. Here, we studied whether silencing of Caspase-3 using carbon nanotube-mediated *in vivo* RNA interference (RNAi) could offer a therapeutic opportunity against stroke. Effective delivery of siRNA directly to the CNS has been shown to normalize phenotypes in animal models of several neurological diseases. It is shown here that peri-lesional stereotactic administration of a Caspase-3 siRNA (siCas 3) delivered by functionalized carbon nanotubes (*f*-CNT) reduced neurodegeneration and promoted functional preservation before and after focal ischemic damage of the rodent motor cortex using an endothelin-1 induced stroke model. These observations illustrate the opportunity offered by carbon nanotube-mediated siRNA delivery and gene silencing of neuronal tissue applicable to a variety of different neuropathological conditions where intervention at well localized brain foci may offer therapeutic and functional benefits.

nanomedicine | neurodegenerative | neuroprotection | neurosciences | gene therapy

Preventing injured neurons from undergoing apoptosis in the acute phase of cerebral ischemia (neuroprotection) is a widely studied strategy to counteract the effects of stroke. The central role of Caspase-3 in regulating cell death (1, 2) processes, constitutes this protease as a prime target for the development of neuroprotective treatments. Indeed, Caspase-3 activation contributes to brain tissue loss and downstream biochemical events leading to programmed cell death after traumatic brain injury (3, 4). Both genetic disruption and pharmacological inhibition of caspases after stroke can reduce ischemic neuronal injury inducing a neuroprotective effect (5–8). It has been suggested that silencing of apoptotic genes using *in vivo* RNA interference (RNAi) could be potentially an effective treatment for stroke (5, 9). Moreover, nonviral delivery of siRNA directly to the Central Nervous System (CNS) has been reported to effectively normalize phenotypes in animal models of several neurological diseases (10–13). However, one of the major challenges is to achieve sufficient *in vivo* delivery of siRNA to target tissues, and into target cells, to induce effective gene silencing. Administration of naked siRNA by continuous pump infusion into the CNS (13) requires high siRNA doses, while the use of lipid transfection reagents or electroporation techniques may induce neuronal tissue damage and cell death (14–16).

Recently, a unique type of nonviral gene vector has emerged, based on functionalized carbon nanotubes (*f*-CNT). Various types of nanotube chemical functionalization approaches have led to improvements of their dispersibility in physiological media

that broaden the spectrum of potential biological applications (17–19). *f*-CNT possess unique features that make them extremely attractive for the construction of unique gene delivery vectors. Most importantly, *f*-CNT have the ability to interact with biological components and be internalized efficiently in different cell types by different mechanisms (20–22). Several studies have shown promising results, exploiting *f*-CNT characteristics for pDNA and siRNA delivery *in vitro* and *in vivo* (17, 18, 20, 23–28). Chemically functionalized single-walled CNT have been able to deliver siRNA to knockdown the expression of telomerase reverse transcriptase in an Lewis Lung Carcinoma mouse tumor model (26). We have recently demonstrated that therapeutic silencing using ammonium functionalized multiwalled carbon nanotube-mediated siRNA delivery can lead to tumor growth arrest and prolonged survival of animals bearing a human lung tumor xenograft (Calu 6) (28). Some of us have also previously reported that Pluronic F127-coated CNT injected into the cerebral cortex did not induce any adverse toxicological effects (29).

Based on previous findings that biocompatible *f*-CNTs are effective intracellular transporters for siRNA and that down-regulation of the Caspase-3 gene can aid recovery after ischemic attack, we hypothesized in this work that *f*-CNT can act as nanoscale devices for the delivery of Caspase-3 siRNA (siCas 3) into neurons of the rodent motor cortex and lead to protection against ischemic insult. Herein we show that peri-lesional, stereotactic administration of siCas 3 delivered by *f*-CNT led to neuroprotection after focal ischemic damage induced by Endothelin-1 (ET-1) in the motor cortex of mice and rats, which promoted functional recovery as shown by the functional “skilled reaching” test in living rats.

## Results and Discussion

**Chemical Functionalization of CNTs.** Chemical functionalization of nanotubes was achieved by introducing an ammonium group onto the multiwalled carbon nanotube (MWNT) backbone using the 1,3-dipolar cycloaddition reaction as described previously (30, 31). The chemical structure of the *f*-CNT studied is shown in Fig. 1A. Chemical functionalization has shown to significantly improve the aqueous dispersibility and individualization of the

Author contributions: K.T.A.-J., L.G., G.B., A.B., M.P., K.K., and T.P. designed research; K.T.A.-J., L.G., G.B., A.N., C.G., C.B., and M.A.H. performed research; K.T.A.-J., L.G., G.B., A.B., M.P., K.K., and T.P. analyzed data; and K.T.A.-J., L.G., G.B., A.B., K.K., and T.P. wrote the paper.

The authors declare no conflict of interest.

\*This Direct Submission article had a prearranged editor.

<sup>1</sup>K.T.A.-J., L.G., and G.B. contributed equally to this work.

<sup>2</sup>Present address: IIT@NEST, Center for Nanotechnology Innovation, 56127 Pisa, Italy.


<sup>3</sup>To whom correspondence may be addressed. E-mail: tommaso@in.cnr.it or kostas.kostarelos@pharmacy.ac.uk.

This article contains supporting information online at [www.pnas.org/lookup/suppl/doi:10.1073/pnas.1100930108/-DCSupplemental](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1100930108/-DCSupplemental).

MWNTs manifested in the quality of their aqueous dispersion in 5% dextrose, in comparison to pristine CNT which required the addition of a dispersing agent or surfactant. The improved dispersibility of the *f*-MWNTs was confirmed by transmission electron microscopy (TEM) (Fig. 1A, Fig. S14). Pristine carbon nanotubes used in this work had a length between 0.5 and 2 μm and average diameter of 20–30 nm. Following the 1,3-dipolar cycloaddition reaction, the morphology and the length of the nanotubes were not markedly affected. Most of the nanotubes (>80%) were below 1 μm long. The length distribution of *f*-MWNT used in this study based on TEM analysis is shown in Fig. S1B. Ammonium functional groups corresponded to 0.147 mmol/g material, as determined by Kaiser Test and thermogravimetric analysis (TGA) (Fig. S1C).

**Cytoplasmic Delivery of siRNA in Primary Neuronal Cultures In Vitro.** We have recently reported the ability of this type of chemically functionalized CNT to complex and transfer siRNA into mammalian cells (27, 28, 32). To confirm such results in neurons, noncoding siRNA fluorescently labeled with AlexaFluor 546 (siNEG-AF546) was complexed with *f*-CNT at 1:8 mass ratio and incubated for 24 h with primary neurons isolated from the mouse motor cortex. Epifluorescence imaging (Fig. 1B) indicated that siNEG-AF546 signals were higher into neurons treated with the complexes in comparison to neurons treated with siNEG-AF546 alone. Confocal laser scanning microscopy (CLSM) confirmed that the fluorescence signal was localized within the cells and that siRNA was not only bound to the plasma membrane. This data indicated that *f*-CNT could effectively transport siRNA into primary neurons in agreement with previous studies using other cell types.


**Caspase-3 Silencing in Murine Neuro2a (N2a) Cells In Vitro.** In order to validate the siCas 3 sequence in vitro, the mouse neuroblastoma N2a cells were incubated with *f*-CNT:siCas 3 complexes (8:1 mass ratio) for 24 h or 48 h. The level of full length caspase-3 (35 kDa) expression in N2a cells was assessed by rtPCR and



**Fig. 1.** Neuronal uptake of *f*-CNT: Alexa Fluor 546-labeled siNEG (siNEG-AF 549) complex in vitro. (A) Chemical structure of *f*-CNT and TEM images of *f*-CNT dispersed in 5% dextrose at 250 μg/mL final concentration. (B) Epifluorescence and confocal laser scanning microscopy (CLSM) images of primary neuronal culture isolated from mouse brain motor cortex and incubated with media containing free uncomplexed siNEG-AF 549 (100 nM) or *f*-CNT:siNEG-AF 549 complex (8:1 mass ratio) for 24 h. siRNA uptake is shown in red.

Western blotting. Fig. 2A shows that preincubation of N2a cells with *f*-CNT:siCas 3 complexes decreased the number of mRNA copies of the full length Caspase-3 to 62% ± 7% at 24 h, and by 69% ± 8% at 48 h posttreatment by rtPCR as a percentage of naive cells. The same results were not seen in cells treated with the vehicle alone (5% dextrose), siCas 3 alone or noncoding siRNA (siNEG) complexed with *f*-CNT at the same mass ratio. Similarly, Western blot analysis at 48 h posttreatment showed that full length Caspase-3 expression in the *f*-CNT:siCas 3 treated group was significantly ( $p < 0.05$ ) decreased compared to all other treated groups (Fig. 2B and C), with a reduction of 56.0% ± 16.0% in Caspase-3 level as a percentage of naive cells. GAPDH was used as housekeeping gene and no change in its expression was observed in all test groups. This data validated the siCas 3 sequence used in this experiment and indicated that siCas delivered into cells is biologically active.

**Internalization of *f*-CNT by Neurons In Vivo.** Several studies have been performed showing internalization of *f*-CNTs into variety



**Fig. 2.** Silencing of Caspase-3 in murine Neuro2A (N2a) neuroblastoma cell line by *f*-CNT:siCaspase-3 (siCas 3) complexes. (A) mRNA expression levels of full length caspase-3 (35 kDa) in N2a cells was analyzed by real time PCR ( $n = 3$ ) after treatment with siCas 3 alone, *f*-CNT:siCas 3 or *f*-CNT:siNEG complexes. Cells were incubated with the complexes for 4 h at 37 °C, and analyzed for mRNA expression after 24 or 48 h posttransfection. Both β-actin and total RNA were used as internal controls. Full length Caspase-3 mRNA level was reduced only in cells treated with *f*-CNT:siCas 3 complexes at both time points. Error bars indicate means + SEM (B) Western blot of N2a cells treated as in (A) and assessed 48 h posttransfection. Full length Caspase-3 was detected by a Caspase-3 antibody. Caspase-3 silencing was seen when N2a cells were pretreated with *f*-CNT:siCas 3 but not with uncomplexed siCas 3 or *f*-CNT:siNEG. No difference in band intensity was seen for GAPDH housekeeping gene in all treated groups. (C) Quantification of full length Caspase-3 silencing, the *ordinate* shows the normalized band intensity of full length Caspase-3 which was significantly reduced compared to its level in siCas 3 alone or *f*-CNT:siNEG treated groups (\*,  $p < 0.05$ ,  $n = 3$ ).


of cells *in vitro* and *in vivo* (17, 33–36). In this study, we directly administered stereotactically *f*-CNT (without siRNA) into the brain cortex to confirm their ability to be internalized by neuronal cells *in vivo*. Intraparenchymal injection of *f*-CNT into the motor cortex resulted in *f*-CNT internalization by a variety of brain cells within 48 h as shown by TEM of brain sections (Fig. 3A). Neurons were able to internalize *f*-CNTs (Fig. 3B and C) and TEM images showed that *f*-CNTs located within the cytoplasm of neurons were individualized (Fig. 3D). Cell types were identified based on their morphological characteristics. Neurons were identified by the large round nucleus, and by the large number of organelles, including mitochondria (M) and Golgi apparatus (G). *f*-CNT were also found to internalize into other types of neuronal cells *in vivo* (Fig. S2). Furthermore, to confirm the capacity of primary neurons to internalize *f*-CNT, an isolated primary neuronal culture was incubated with *f*-CNT for 24 h, and cells were imaged either intact by cryo-SEM or sectioned and imaged by TEM. These microscopic techniques confirmed that nanotubes were able to bind and translocate the plasma membrane of neurons (cryo-SEM) and localize intracellularly (TEM) (Fig. S3).

***f*-CNT:siCas 3 Complex Treatment Before and After Endothelin-1 (ET-1) Exposure Decreases Expression of TUNEL in Murine Brain Cortex *In Vivo*.** To determine the silencing efficiency of *f*-CNT:siCas 3 *in vivo*, the ET-1 model of focal stroke was employed. ET-1 is a potent vasoconstrictor that has been used to induce ischemic injury resembling a thrombo-embolic stroke event (37) when injected directly into rodent brain. In the treatment protocol before ET-1 exposure, mice were pretreated (1  $\mu$ L) with the vehicle alone (5% dextrose), siCas 3 (4.7 pmol), or the *f*-CNT:siRNA complexes (8:1 mass ratio), and after 24 h reinjected at the same site with ET-1 (+ET-1 group) to induce ischemic injury (Fig. 4A). The group of 5% dextrose-treated animals was reinjected with vehicle alone (-ET-1 group). All injections were aimed at the cortical area containing the representation of the forelimb and neuroprotection was studied by TUNEL staining (apoptotic cells only) (Fig. 4B). Previous studies have indicated that injury-induced apoptosis can be detected from hours to days following induced injury and may contribute to neurological dysfunction.

Therefore, TUNEL staining was performed on brain sections 24 h after ET-1 injection (48 h posttreatment). As expected, TUNEL-positive cells were observed in the +ET-1 group preinjected with 5% dextrose ( $156.0 \pm 15.3$  cells/mm<sup>2</sup>) mainly in the penumbra area compared to only  $80.8 \pm 16.7$  cells/mm<sup>2</sup> in -ET-1 group (Fig. 4). Only the group preinjected with *f*-CNT:siCas 3 (+ET-1) led to statistically significant reduction ( $p \leq 0.05$ ) in the number of apoptotic cells ( $83.0 \pm 18.0$  cells/mm<sup>2</sup>) compared to +ET-1 group preinjected with 5% dextrose (Fig. 4). No significant neuroprotection was detected in brains preinjected with siCas 3 alone or noncoding siRNA (siNEG) complexed with *f*-CNT at the same mass ratio, indicating the specific biological activity of siCas delivered by *f*-CNT.


It was considered prudent and clinically relevant to also perform this experiment after the ET-1 induced ischemic damage had been initiated to assess the siRNA treatment. *f*-CNT:siCas 3 complexes were stereotactically injected 1 h postischemic damage. We observed that the number of apoptotic cells in the penumbra area decreased mostly in the *f*-CNT:siCas 3 treated group in comparison to 5% dextrose or free siCas 3 treated groups (Fig. 5), however this trend was not statistically significant as seen in the case of the treatment protocol before ischemic damage was induced. Similar observations of moderate therapeutic effects obtained postischemic damage induction (compared to pretreatment) have previously been reported for other therapeutic modalities (6). We therefore concluded that a neuroprotective effect could be reproducibly obtained from a single *f*-CNT:siCas 3 stereotactic administration before and after ET-1 induced ischemic damage, however more significant effects were obtained when the treatment was carried out prior to the ischemic insult.

**“Skilled Reach” Assay in Rats.** In order to study if the neuroprotective effect observed in the brain cortex was sufficient to warrant a significant improvement in the behavior of treated animals, the functional *skilled reaching* test in rats was used. Damage of the forelimb representation area of the motor cortex results in impaired reaching and grasping movements of the contralateral forelimb that can be evaluated using the *skilled reaching* test. This



**Fig. 3.** Internalization of *f*-CNT by neuronal tissue *in vivo*. TEM of brain cortical parenchyma at 48 h after stereotactic administration of *f*-CNT showing nanotubes internalization into brain cells (A). Cells are identified by their morphological characteristics; neurons are marked by a dotted line and zoomed in with internalized *f*-CNT marked in a square. G, M, and N stands for Golgi apparatus, mitochondria, and nucleus respectively (B–D).





**Fig. 6.** Behavioral analysis using “skilled reaching” test in rats. Functional improvement in ET-1 ischemic rat forelimb function with or without pretreatment was measured. Rats were pretreated with 5% dextrose, siCas 3 alone (4.7 pmol), *f*-CNT:siCas 3 or *f*-CNT:siNEG complexes (8:1 mass ratio) 24 h before exposure to ET-1 (30 pmol) leading to unilateral lesions made contralateral to the preferred (for reaching) forelimb. During recall, rats treated with *f*-CNT:siCas 3 performed a significant higher number of positive trials in food pellet reaching compared to all other treatment groups. (\*,  $p \leq 0.05$ ; \*\*,  $p \leq 0.01$ ,  $n = 4$ ) and reaching prelesion levels

stroke. In another study by Karatas et al. (6), it was reported that the systemic delivery of chitosan nanospheres targeting the transferrin receptor and encapsulating a peptide caspase-3 inhibitor provided neuroprotection in mice subjected to 2 h of middle cerebral artery occlusion and 24 h of reperfusion. Both studies have directly or indirectly validated Caspase-3 as a target, however neither established Caspase-3 silencing by RNA interference as a possible therapeutic approach to be explored. Moreover, functional recovery and rehabilitation was not studied in order to assess the efficacy of either treatment strategies. In agreement with the results obtained in the present study, Karatas et al. (6) showed that treatment before the onset of ischemia was more effective in reducing the infarct volume than treatment after the ischemic insult.

Intriguingly, a very recent study showed that preinfarct intracerebroventricular treatment with amine-functionalized single-walled carbon nanotubes could improve tolerance of neurons to ischemic injury in the middle cerebral artery occlusion stroke model (39). In our experiments, control intraparenchymal injections of a complex between amino-functionalized MWNT and scrambled siRNA did not affect apoptosis or functional recovery after endothelin-induced focal stroke, suggesting little neuroprotective activity of CNTs alone. However, important methodological aspects differ between our experiments and those reported by Lee et al. (e.g., injection of CNT-siRNA complex vs. CNT alone; CNT type, dimensions, manufacturer, dosage, location of injection, and stroke model). Furthermore, in our work a specific biological hypothesis was explored based on the gene silencing of Caspase-3 mediated by effectively delivered siRNA. Further work is indeed required to understand and explore further any potentially beneficial effects of amino-functionalized CNTs in stroke.

This work is a proof-of-principle study demonstrating that in vivo gene silencing of Caspase-3 in neuronal tissue mediated by *f*-CNT:siRNA vectors administered stereotactically can lead to neuroprotection and significant functional improvement before and after ischemic insult. Such an approach can offer more flexibility than the administration of a caspase-3 inhibitor intracerebrally (3) or systemically (6), because siRNA-mediated gene silencing can target any potential mRNA that may be involved in stroke-induced neurodegeneration. In contrast, pharmacological inhibitors can only target certain types of cellular recep-

tors and enzymes. Such an approach could offer genetic-based combinatory modalities to various currently used neurosurgical interventions in a variety of CNS diseases. In particular, neuropathologies for which well localized brain foci are identified and known to be implicated in the phenotypic expression of disease (such as stroke and Parkinson’s disease). Further work is needed in order to determine any implications and residence patterns of carbon nanotubes within cerebral tissue, the viability of stereotactic administration, and the therapeutic validity for the best target gene. Moreover, further studies are needed to improve the observed neuroprotective effect following ischemic insults in order to determine the clinical relevance of such approaches for post cerebral stroke treated patients. Overall, effective stereotactic administration of nanotube-mediated gene silencing with functional improvements, even though clinically more challenging compared to systemic treatment strategies (40, 41), can offer significant benefits for a variety of currently untreatable debilitating neuropathologies.

## Experimental Methods

**Carbon Nanotubes and Other Chemicals.** All details are described in *SI Text*.

**Chemical Functionalization and Characterization of Carbon Nanotubes.** *f*-CNT were prepared following the 1,3 dipolar cycloaddition reaction as previously described (30, 31). Details of chemical functionalization procedures are described in *SI Text*.

**Transmission Electron Microscopy (TEM) of *f*-CNT Dispersions and Brain Sections.** TEM processing of brain tissues is described in *SI Text*.

**Cell Cultures.** N2A cell culture was performed as described in *SI Text*.

**Evaluation of Fluorescent siRNA Complex Uptake in Primary Neurons.** All details are described in *SI Text*.

**In Vitro Silencing of Caspase-3 in N2a Cells.** All details are described in *SI Text*.

**Western Blot and Real Time PCR (rtPCR).** The experimental procedures of Western blotting and rtPCR are described in *SI Text*.

**Animal Handling Procedures.** All animal experiments were performed in compliance with the United Kingdom Home Office (1989) and Code of Practice for the housing and care of Animals used in Scientific Procedures and in agreement with protocols approved by the Italian Ministry for Scientific Research. More details are described in *SI Text*.

***f*-CNT:siRNA Complexation for In Vivo Studies.** siRNA complex preparation for in vivo experiments was prepared by adding an equal volume of *f*-CNT dispersion (1 mg/mL in 10% dextrose) to siRNA (siCas 3 or siNEG) solution (10  $\mu$ M or 125  $\mu$ g/mL in water), mixed by rapid pipetting, to achieve *f*-CNT:siRNA mass ratio of  $\sim$ 8:1. One microlitre containing the complex of 500 ng *f*-CNT and 62.5 ng (4.7 pmol) siRNA was injected into the cerebral cortex of each animal. For comparison, groups of mice were injected with 1  $\mu$ L containing the vehicle alone (5% dextrose), *f*-CNT (500 ng) complexed with siNEG or uncomplexed siCas 3 (62.5 ng) in 5% dextrose.

**Stereotactic Administration of *f*-CNT or *f*-CNT:siRNA Complexes.** Mice or rats were anesthetized with Avertin (0.5 mL/100 g) and secured on a stereotactic apparatus. Injections were made at stereotactic locations (at one site in mice: +0.5 mmAP, +1.5 mmML

from bregma; at two sites in rats: 0 mm, +2.5 mmML, +2.5 mmML, +2.3 mmAP from bregma) in the primary motor cortex by means of a glass pipette (30- $\mu$ m tip diameter) mounted on a motorized (0.1- $\mu$ m step) three-axis micromanipulator (Sutter Instruments) connected to a manual injector. In mice, a total of 1  $\mu$ L of *f*-CNT (500 ng) dispersion was released at 700  $\mu$ m below the cortical surface. In rats, a total of 500 nL was released at 700  $\mu$ m below the cortical surface and another 500 nL was released 400  $\mu$ m below the cortical surface to allow homogeneous dispersion of *f*-CNTs along the cortical depth at the two sites of injection. More details are described in *SI Text*.

**Endothelin (ET-1) Stroke Model.** All details are described in *SI Text*.

**TUNEL Staining for Apoptosis Detection.** The TUNEL staining procedure is described in more details in *SI Text*.

**The Skilled Reaching Test.** The reaching test was performed in adult rats. All experimental details are described in *SI Text*.

**ACKNOWLEDGEMENTS.** This work was supported by the following grants: European Commission FP6 NINIVE (to K.K. and T.P.), FP7 ANTICARB (to K.K., M.P., and A.B.), FP7 PLASTICISE (to T.P.), and the United Kingdom EPSRC "Nanotechnology Grand Challenges: Healthcare" (to K.K. and K.T.A.-J.), EXTRAPLAST IIT (to T.P.), the CANESTRO project of the Regione Toscana (to T.P.). A.B. wishes to thank the Centre National de la Recherche Scientifique (CNRS).

- Budihardjo I, Oliver H, Lutter M, Luo X, Wang X (1999) Biochemical pathways of caspase activation during apoptosis. *Annu Rev Cell Dev Biol* 15:269–290.
- Slee EA, Adrain C, Martin SJ (1999) Serial killers: ordering caspase activation events in apoptosis. *Cell Death Differ* 6:1067–1074.
- Clark RS, et al. (2000) Caspase-3 mediated neuronal death after traumatic brain injury in rats. *J Neurochem* 74:740–753.
- Namura S, et al. (1998) Activation and cleavage of caspase-3 in apoptosis induced by experimental cerebral ischemia. *J Neurosci* 18:3659–3668.
- Chu Y, Miller JD, Heistad DD (2007) Gene therapy for stroke: 2006 overview. *Curr Hypertens Rep* 9:19–24.
- Karatas H, et al. (2009) A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. *J Neurosci* 29:13761–13769.
- Schielke GP, Yang GY, Shivers BD, Betz AL (1998) Reduced ischemic brain injury in interleukin-1 beta converting enzyme-deficient mice. *J Cereb Blood Flow Metab* 18:180–185.
- Rabuffetti M, et al. (2000) Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines. *J Neurosci* 20:4398–4404.
- Chen C, et al. (2009) Early inhibition of HIF-1 $\alpha$  with small interfering RNA reduces ischemic-reperfused brain injury in rats. *Neurobiol Dis* 33:509–517.
- Kumar P, Lee SK, Shankar P, Manjunath N (2006) Transvascular delivery of small interfering RNA to the central nervous system. *PLoS Med* 3:e96.
- Thakker DR, et al. (2005) siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain. *Mol Psychiatry* 10:782–789 714.
- Wang YL, et al. (2005) Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. *Neurosci Res* 53:241–249.
- Dorn G, et al. (2004) siRNA relieves chronic neuropathic pain. *Nucleic Acids Res* 32:e49.
- Gaudilliere B, Shi Y, Bonni A (2002) RNA interference reveals a requirement for myocyte enhancer factor 2A in activity-dependent neuronal survival. *J Biol Chem* 277:46442–46446.
- Krichevsky AM, Kosik KS (2002) RNAi functions in cultured mammalian neurons. *Proc Natl Acad Sci USA* 99:11926–11929.
- Torocsik B, Angelastro JM, Greene LA (2002) The basic region and leucine zipper transcription factor MafK is a new nerve growth factor-responsive immediate early gene that regulates neurite outgrowth. *J Neurosci* 22:8971–8980.
- Pantarotto D, et al. (2004) Functionalized carbon nanotubes for plasmid DNA gene delivery. *Angew Chem Int Ed Engl* 43:5242–5246.
- Singh R, et al. (2005) Binding and condensation of plasmid DNA onto functionalized carbon nanotubes: toward the construction of nanotube-based gene delivery vectors. *J Am Chem Soc* 127:4388–4396.
- Kostarelou K, Bianco A, Prato M (2009) Promises, facts and challenges for carbon nanotubes in imaging and therapeutics. *Nat Nanotechnol* 4:627–633.
- Gao L, et al. (2006) Carbon nanotube delivery of the GFP gene into mammalian cells. *ChemBiochem* 7:239–242.
- Lacerda L, et al. (2007) Intracellular trafficking of carbon nanotubes by confocal laser scanning microscopy. *Adv Mater* 19:1480–1484.
- Lacerda L, Raffa S, Prato M, Bianco A, Kostarelou K (2007) Cell-penetrating CNTs for delivery of therapeutics. *Nano Today* 2:38–43.
- Cai D, et al. (2008) Interaction between carbon nanotubes and mammalian cells; characterization by flow cytometry and application. *Nanotechnology* 19:1–10.
- Kam NW, Liu Z, Dai H (2005) Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. *J Am Chem Soc* 127:12492–12493.
- Liu Y, et al. (2005) Polyethylenimine-grafted multiwalled carbon nanotubes for secure noncovalent immobilization and efficient delivery of DNA. *Angew Chem Int Ed Engl* 44:4782–4785.
- Zhang Z, et al. (2006) Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. *Clin Cancer Res* 12:4933–4939.
- Herrera MA, et al. (2009) Synthesis and characterization of a carbon nanotube-dendron series for efficient siRNA delivery. *J Am Chem Soc* 131:9843–9848.
- Podesta JE, et al. (2009) Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. *Small* 5:1176–1185.
- Bardi G, et al. (2009) Pluronic-coated carbon nanotubes do not induce degeneration of cortical neurons in vivo and in vitro. *Nanomedicine-NBM* 5:96–104.
- Georgakilas V, et al. (2002) Amino acid functionalisation of water soluble carbon nanotubes. *Chem Commun* 24:3050–3051.
- Georgakilas V, et al. (2002) Purification of HiPCO carbon nanotubes via organic functionalization. *J Am Chem Soc* 124:14318–14319.
- Al-Jamal KT, et al. (2010) Enhanced cellular internalization and gene silencing with a series of cationic dendron-multiwalled carbon nanotube:siRNA complexes. *FASEB J* 24:4354–4365.
- Kostarelou K, et al. (2007) Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. *Nat Nanotechnol* 2:108–113.
- Pantarotto D, Briand JP, Prato M, Bianco A (2004) Translocation of bioactive peptides across cell membranes by carbon nanotubes. *Chem Commun* 1:16–17.
- Zhang L, Alizadeh D, Badie B (2010) Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. *Methods in Molecular Biology* 625:55–65.
- Kateb B, et al. (2007) Internalization of MWCNTs by microglia: possible application in immunotherapy of brain tumors. *Neuroimage* 37(Suppl 1):S9–17.
- Gilmour G, Iversen SD, O'Neill MF, Bannerman DM (2004) The effects of intracortical endothelin-1 injections on skilled forelimb use: implications for modelling recovery of function after stroke. *Behav Brain Res* 150:171–183.
- Matsumoto K, Sato C, Naka Y, Whitby R, Shimizu N (2010) Stimulation of neuronal neurite outgrowth using functionalized carbon nanotubes. *Nanotechnology* 21:115101.
- Lee HJ, et al. (2011) Amine-modified single-walled carbon nanotubes protect neurons from injury in a rat stroke model. *Nat Nanotechnol* 6:121–125.
- Partridge WM (2007) shRNA and siRNA delivery to the brain. *Adv Drug Deliv Rev* 59:141–152.
- Kumar P, et al. (2007) Transvascular delivery of small interfering RNA to the central nervous system. *Nature* 448:39–43.